1. Home
  2. INTS vs LSH Comparison

INTS vs LSH Comparison

Compare INTS & LSH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • INTS
  • LSH
  • Stock Information
  • Founded
  • INTS 2012
  • LSH 2018
  • Country
  • INTS United States
  • LSH United States
  • Employees
  • INTS N/A
  • LSH N/A
  • Industry
  • INTS Biotechnology: Pharmaceutical Preparations
  • LSH
  • Sector
  • INTS Health Care
  • LSH
  • Exchange
  • INTS Nasdaq
  • LSH NYSE
  • Market Cap
  • INTS 8.7M
  • LSH 7.3M
  • IPO Year
  • INTS 2023
  • LSH 2024
  • Fundamental
  • Price
  • INTS $0.46
  • LSH $0.93
  • Analyst Decision
  • INTS Strong Buy
  • LSH
  • Analyst Count
  • INTS 3
  • LSH 0
  • Target Price
  • INTS $8.50
  • LSH N/A
  • AVG Volume (30 Days)
  • INTS 1.3M
  • LSH 47.7K
  • Earning Date
  • INTS 05-13-2025
  • LSH 08-01-2025
  • Dividend Yield
  • INTS N/A
  • LSH N/A
  • EPS Growth
  • INTS N/A
  • LSH N/A
  • EPS
  • INTS N/A
  • LSH N/A
  • Revenue
  • INTS N/A
  • LSH $16,270,095.00
  • Revenue This Year
  • INTS N/A
  • LSH N/A
  • Revenue Next Year
  • INTS N/A
  • LSH N/A
  • P/E Ratio
  • INTS N/A
  • LSH N/A
  • Revenue Growth
  • INTS N/A
  • LSH N/A
  • 52 Week Low
  • INTS $0.29
  • LSH $0.84
  • 52 Week High
  • INTS $5.10
  • LSH $5.37
  • Technical
  • Relative Strength Index (RSI)
  • INTS 38.44
  • LSH N/A
  • Support Level
  • INTS $0.29
  • LSH N/A
  • Resistance Level
  • INTS $0.63
  • LSH N/A
  • Average True Range (ATR)
  • INTS 0.09
  • LSH 0.00
  • MACD
  • INTS 0.06
  • LSH 0.00
  • Stochastic Oscillator
  • INTS 50.88
  • LSH 0.00

About INTS Intensity Therapeutics Inc. Common stock

Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.

About LSH LAKESIDE HOLDING LTD

Lakeside Holding Ltd i an integrated cross-border supply chain solution provider with a strategic focus on the Asian market including China and South Korea. It provides customized cross-border ocean freight solutions and airfreight solutions in the U.S, including cross-border freight consolidation and forwarding services; customs clearance services; warehousing and distribution services and U.S. domestic ground transportation services.

Share on Social Networks: